Peripheral artery disease (PAD) is associated with exercise impairment and greater thrombotic risk. We investigated whether clot formation and platelet aggregation assessed by thromboelastography and light-transmission aggregometry correlate with the severity of symptomatic PAD assessed by ambulatory function measures. We studied 40 symptomatic patients with PAD in whom severity of disease was assessed using ankle–brachial index, peak walking time (PWT), claudication onset time, peak oxygen uptake, daily ambulatory activity, and walking impairment questionnaire (WIQ) scores. Clot strength correlated negatively with peak oxygen uptake, PWT, WIQ distance, and stair-climbing scores. Time to clot formation did not correlate with exercise parameters. Platelet aggregation was negatively correlated with WIQ distance score and was positively correlated with PWT and peak oxygen uptake. In conclusion, clot strength and platelet aggregation correlated with objective and self-perceived ambulatory measures. Patients with PAD having more severe walking impairment may be likely to form stronger clots.
RosamondWFlegalKFurieK. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146.
2.
McDermottMM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med. 2006;73(suppl 4):S2–S7.
3.
MilaniRVLavieCJ. The role of exercise training in peripheral arterial disease. Vasc Med. 2007;12(4):351–358.
4.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
5.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339.
6.
BergerJSKrantzMJKittelsonJMHiattWR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–1919.
RajagopalanSMcKayIFordIBachooPGreavesMBrittendenJ. Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management. J Vasc Surg. 2007;46(3):485–490.
9.
CassarKBachooPBrittendenJ. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2003;25(1):6–15.
10.
BuchholzAMBruchLSchulteKL. Activation of circulating platelets in patients with peripheral arterial disease during digital subtraction angiography and percutaneous transluminal angioplasty. Thromb Res. 2003;109(1):13–22.
11.
RoblessPAOkonkoDLintottPMansfieldAOMikhailidisDPStansbyGP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003;25(1):16–22.
12.
CassarKBachooPFordIGreavesMBrittendenJ. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. 2003;38(1):99–103.
13.
KomarovAPanchenkoEDobrovolskyA. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J. 2002;23(16):1309–1316.
14.
ReiningerCBGrafJReiningerAJSpannaglMSteckmeierBSchweibererL. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res. 1996;82(6):523–532.
15.
TanKTTayebjeeMHLyndCBlannADLipGY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med. 2005;37(1):61–66.
16.
BraunOOJagroopAWangLMikhailidisDPBurnstockGErlingeD. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study. Platelets. 2005;16(5):261–267.
17.
KokschMZeigerFWittigK. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2001;21(2):147–154.
18.
SmithTDhunnooGMohanICharlton-MenysV. A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease. Platelets. 2007;18(4):245–248.
19.
UndasANowakowskiTCiesla-DulMSadowskiJ. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis. 2011;215(2):481–486.
20.
GardnerAWParkerDEMontgomeryPSScottKJBlevinsSM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation. 2011;123(5):491–498.
21.
EikelboomJWHirshJSpencerFABaglinTPWeitzJI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e89S–119S.
22.
GardnerAWMontgomeryPS. The Baltimore activity scale for intermittent claudication: a validation study. Vasc Endovasc Surg. 2006;40(5):383–391.
23.
CoyneKSMargolisMKGilchristKA. Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg. 2003;38(2):296–304.
24.
GardnerAW. Reliability of transcutaneous oximeter electrode heating power during exercise in patients with intermittent claudication. Angiology. 1997;48(3):229–235.
25.
JagroopIAMatsagasMIGeroulakosGMikhailidisDP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 2004;15(2):117–125.
26.
HongYGengoFMRainkaMMBatesVEMagerDE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin pharmacokinetics. 2008;47(2):129–137.
